2012
Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease
Tawara I, Sun Y, Liu C, Toubai T, Nieves E, Evers R, Alrubaie M, Mathewson N, Tamaki H, Reddy P. Donor- but not host-derived interleukin-10 contributes to the regulation of experimental graft-versus-host disease. Journal Of Leukocyte Biology 2012, 91: 667-675. PMID: 22262800, PMCID: PMC3317273, DOI: 10.1189/jlb.1011510.Peer-Reviewed Original ResearchConceptsSuppression of GVHDSeverity of GVHDIL-10Donor TregsBM graftsRegulation of GVHDImmune-regulatory cytokinesInterleukin-10 contributeAcute GVHDClinical GVHDGVHD severityHost diseaseDonor graftsGVHDPreclinical modelsTregsGene polymorphismsExperimental graftCellular subsetsGraftSeverityHost cellsFunctional relevanceHost tissuesIL
2011
Donor but Not the Host Derived Interleukin-10 (IL-10) Contributes to Regulation of Graft-Versus-Host Disease (GVHD)
Tawara I, Sun Y, Liu C, Toubai T, Reddy P. Donor but Not the Host Derived Interleukin-10 (IL-10) Contributes to Regulation of Graft-Versus-Host Disease (GVHD). Blood 2011, 118: 2975. DOI: 10.1182/blood.v118.21.2975.2975.Peer-Reviewed Original ResearchT cell-depleted bone marrowT effector cellsDonor TregsIL-10B6 donorsEffector cellsAllogeneic animalsAcute GVHDDonor BMGVHD mortalityGVHD severityT effectorsT cellsNon-hematopoietic cellsWT B6B6 miceB6 animalsDonor regulatory T cellsT cell-depleted BMRegulation of GVHDSuppression of GVHDWT B6 miceIL-10 deficiencySeverity of GVHDIL-10 secretion
2010
A Crucial Role for Host APCs in the Induction of Donor CD4+CD25+ Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease
Tawara I, Shlomchik WD, Jones A, Zou W, Nieves E, Liu C, Toubai T, Duran-Struuck R, Sun Y, Clouthier SG, Evers R, Lowler KP, Levy RB, Reddy P. A Crucial Role for Host APCs in the Induction of Donor CD4+CD25+ Regulatory T Cell-Mediated Suppression of Experimental Graft-versus-Host Disease. The Journal Of Immunology 2010, 185: 3866-3872. PMID: 20810991, PMCID: PMC2981818, DOI: 10.4049/jimmunol.1001625.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntigen PresentationAntigen-Presenting CellsBone Marrow TransplantationCell SeparationDisease Models, AnimalFlow CytometryGraft vs Host DiseaseHistocompatibility Antigens Class IIInterleukin-2 Receptor alpha SubunitLymphocyte ActivationMiceMice, Inbred BALB CMice, Inbred C57BLT-Lymphocyte SubsetsT-Lymphocytes, RegulatoryConceptsSuppression of GVHDDonor T cellsHost APCsBone marrow transplantationDonor TregsT cellsHost diseaseMarrow transplantationRegulatory T cell-mediated suppressionAlloreactive donor T cellsAllogeneic bone marrow transplantationT cell-mediated suppressionInduction of donorInduction of GVHDRegulatory T cellsCell-mediated suppressionDevelopment of graftExperimental GVHDGVHD protectionTreg numbersIL-10Nonmalignant diseasesAlloantigen expressionGVHDMurine modelCharacterization of Anti-HCV Antibodies in IL-10-Treated Patients
Eksioglu E, Bess J, Jones G, Dettloff J, Dangmeon P, Dong H, Zhu H, Firpi R, Xu Y, Nelson D, Liu C. Characterization of Anti-HCV Antibodies in IL-10-Treated Patients. Viral Immunology 2010, 23: 359-368. PMID: 20712480, PMCID: PMC2978060, DOI: 10.1089/vim.2009.0095.Peer-Reviewed Original ResearchConceptsAnti-HCV antibodiesAnti-HCV antibody titersIL-10Antibody titersTotal anti-HCV antibodyHepatitis C virus infectionC virus infectionChronic hepatitis patientsIL-10 treatmentReal-time reverse transcriptase-polymerase chain reactionReverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionHuh-7.5 cellsHCV-negative seraAntibody neutralization activityDisease activityHCV antibodiesViral burdenHepatitis patientsViral loadInterleukin-10Antibody responseReplicon cellsPolymerase chain reactionNeutralization antibody
2009
A Crucial Role for Antigen Presenting Cells in Donor CD4+CD25+ Regulatory T Cell Mediated Suppression of Experimental Gvhd.
Tawara I, Toubai T, Malter C, Sun Y, Nieves E, Lowler K, Liu C, Ferrara J, Reddy P. A Crucial Role for Antigen Presenting Cells in Donor CD4+CD25+ Regulatory T Cell Mediated Suppression of Experimental Gvhd. Blood 2009, 114: 688. DOI: 10.1182/blood.v114.22.688.688.Peer-Reviewed Original ResearchHost antigen presenting cellsAntigen presenting cellsGVHD mortalityGVHD protectionT cellsWT recipientsIL-10Effector phaseDonor TregsExperimental GVHDAllo-antigenB6 animalsPresenting cellsClass IIProfessional antigen presenting cellsLack of TregsMaintenance of GVHDRegulation of GVHDResponse of TregsExpansion of CD8Target tissuesRegulatory T cellsT cell effectorsClass II expressionHost target tissuesImmunization with host-type CD8α+ dendritic cells reduces experimental acute GVHD in an IL-10–dependent manner
Toubai T, Malter C, Tawara I, Liu C, Nieves E, Lowler K, Sun Y, Reddy P. Immunization with host-type CD8α+ dendritic cells reduces experimental acute GVHD in an IL-10–dependent manner. Blood 2009, 115: 724-735. PMID: 19965670, PMCID: PMC2810989, DOI: 10.1182/blood-2009-06-229708.Peer-Reviewed Original ResearchConceptsT cell responsesDendritic cellsT cellsImmune responseUndesirable immune responsesIL-10Major histocompatibilityDonor T-cell responsesIL-10-dependent mannerExperimental acute GVHDImmunization of donorsDonor T cellsAntigen-specific mannerB6 modelBALB/c T cellsCertain immune responsesBALB/cAcute GVHDHost diseaseInterleukin-10Active immunizationInflammatory cytokinesVaccination strategiesAntigen specificityGVHD
2004
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera R, Tu Z, Xu Y, Firpi R, Rosen H, Liu C, Nelson D. An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection. Hepatology 2004, 40: 1062-1071. PMID: 15486925, DOI: 10.1002/hep.20454.Peer-Reviewed Original ResearchMeSH KeywordsAntibodiesAntibody FormationAntigens, CDCase-Control StudiesCD4-Positive T-LymphocytesCD8-Positive T-LymphocytesCell CommunicationEpitopesHepatitis CHepatitis C AntigensHumansImmune SystemInterleukin-10PhenotypeReceptors, Interleukin-2Transforming Growth Factor betaTransforming Growth Factor beta1ConceptsHepatitis C virus infectionPeripheral blood mononuclear cellsC virus infectionRegulatory T lymphocytesBlood mononuclear cellsT lymphocytesMononuclear cellsVirus infectionHCV-specific T-cell responsesCell-cell contact mannerT cell immune responsesHCV RNA titersT cell frequenciesIL-10 productionT cell responsesCell immune responsesInterferon-gamma productionLiver inflammatory activityNormal control subjectsT cell proliferationInterferon gamma activityGrowth factor betaIL-10Intracellular cytokinesInflammatory activity
2003
Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect
Nelson D, Tu Z, Soldevila‐Pico C, Abdelmalek M, Zhu H, Xu Y, Cabrera R, Liu C, Davis G. Long‐term interleukin 10 therapy in chronic hepatitis C patients has a proviral and anti‐inflammatory effect. Hepatology 2003, 38: 859-868. PMID: 14512873, DOI: 10.1002/hep.1840380412.Peer-Reviewed Original ResearchConceptsIL-10HCV RNASerum ALTCytokine productionChronic hepatitis C patientsFunctional T cell analysesSerum HCV RNA levelsHCV-specific CD4Hepatic inflammation scoresIL-10 administrationInterleukin-10 therapyPBMC cytokine productionTh2 dominant profileHCV RNA levelsHepatitis C patientsT cell analysisTh2 cytokine productionAnti-inflammatory effectsAcute flaresC patientsDisease activityMeq/mLViral burdenAdvanced fibrosisLiver biopsy